Louisiana State Employees Retirement System Buys Shares of 14,000 Collegium Pharmaceutical, Inc. $COLL

Louisiana State Employees Retirement System purchased a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 14,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $463,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Ritholtz Wealth Management boosted its stake in shares of Collegium Pharmaceutical by 35.1% during the first quarter. Ritholtz Wealth Management now owns 8,283 shares of the specialty pharmaceutical company’s stock valued at $274,000 after acquiring an additional 2,150 shares during the last quarter. SG Americas Securities LLC increased its position in Collegium Pharmaceutical by 284.4% during the 1st quarter. SG Americas Securities LLC now owns 66,397 shares of the specialty pharmaceutical company’s stock worth $2,196,000 after purchasing an additional 49,123 shares in the last quarter. Evolve Private Wealth LLC raised its stake in Collegium Pharmaceutical by 5.9% in the 1st quarter. Evolve Private Wealth LLC now owns 23,520 shares of the specialty pharmaceutical company’s stock valued at $778,000 after purchasing an additional 1,313 shares during the last quarter. Balboa Wealth Partners raised its stake in Collegium Pharmaceutical by 57.7% in the 1st quarter. Balboa Wealth Partners now owns 7,115 shares of the specialty pharmaceutical company’s stock valued at $235,000 after purchasing an additional 2,603 shares during the last quarter. Finally, Hsbc Holdings PLC lifted its holdings in Collegium Pharmaceutical by 78.0% in the 4th quarter. Hsbc Holdings PLC now owns 30,854 shares of the specialty pharmaceutical company’s stock valued at $1,429,000 after purchasing an additional 13,520 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Needham & Company LLC reissued a “buy” rating and set a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday. Finally, Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $57.50.

Collegium Pharmaceutical Trading Down 1.7%

Shares of COLL stock opened at $35.83 on Thursday. The firm’s 50-day simple moving average is $34.60 and its 200-day simple moving average is $38.93. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62. Collegium Pharmaceutical, Inc. has a 1-year low of $29.19 and a 1-year high of $50.79. The firm has a market cap of $1.16 billion, a P/E ratio of 17.56 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. The firm had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. Collegium Pharmaceutical’s revenue was up 8.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.49 earnings per share. As a group, equities analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.